Functional efficacy of adenosine A 2A receptor agonists is positively correlated to their receptor residence time

British Journal of Pharmacology

Volumn 166, Issue 6, 2012, Pages 1846-1859

  Guo, Dong ^a   Mulder Krieger, Thea ^a   IJzerman, Adriaan P ^a   Heitman, Laura H ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adenosine A 2A receptor; Binding kinetics; Efficacy; Impedance; Label free technology; Residence time

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE RECEPTOR STIMULATING AGENT; CYCLIC AMP; LUF 5448; LUF 5449; LUF 5550; LUF 5631; LUF 5833; LUF 5834; LUF 5835; UK 432097; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CELL ASSAY; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TEMPERATURE SENSITIVITY;

ADENOSINE A2 RECEPTOR AGONISTS; BINDING, COMPETITIVE; HEK293 CELLS; HUMANS; KINETICS; LIGANDS; RADIOLIGAND ASSAY; RECEPTORS, ADENOSINE A2; TIME FACTORS;

EID: 84863228021     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01897.x     Document Type: Article

References (47)

1. 3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists. Proc Natl Acad Sci USA 82: 925-929.
2. Ballesteros JA, Weinstein H (1995). Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci 25: 366-428.
3. 2Breceptor with an improved selectivity profile compared to the reference agonist N- ethylcarboxamidoadenosine. J Med Chem 47: 3707-3709.
4. Black JW, Leff P (1983). Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220: 141-162. (Pubitemid 14217337)
5. 2A adenosine receptors. Life Sci 59: 1373-1388.
6. 2 receptors. Naunyn Schmiedebergs Arch Pharmacol 335: 64-69.
7. 2A receptor interacts with the actin-binding protein α-actinin. J Biol Chem 278: 37545-37552.
8. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
9. Contreras ML, Wolfe BB, Molinoff PB (1986). Kinetic analysis of the interactions of agonists and antagonists with beta adrenergic receptors. J Pharmacol Exp Ther 239: 136-143. (Pubitemid 16006348)
10. Copeland RA (2005). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. Wiley: New York.
11. Copeland RA, Pompliano DL, Meek TD (2006). Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5: 730-739. (Pubitemid 44323700)
12. 2+ channel-dependent oscillations of morphology in human H295R adrenoma cells. Biochim Biophys Acta 1813: 754-762.
13. 3H]-SCH 58261. Br J Pharmacol 121: 353-360.
14. Dowling MR, Charlton SJ (2006). Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol 148: 927-937. (Pubitemid 44543610)
15. Flynn AN, Tillu DV, Asiedu MN, Hoffman J, Vagner J, Price TJ et al. (2011). The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl- LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo. J Biol Chem 286: 19076-19088.
16. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001). International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552. (Pubitemid 33136237)
17. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE (2011). International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - an update. Pharmacol Rev 63: 1-34.
18. Gao ZG, Jacobson KA (2007). Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 12: 479-492.
19. Hoeren M, Brawek B, Mantovani M, Loffler M, Steffens M, van Velthoven V et al. (2008). Partial agonism at the human alpha(2A)-autoreceptor: role of binding duration. Naunyn Schmiedebergs Arch Pharmacol 378: 17-26.
20. 2A adenosine receptor bound to an antagonist. Science 322: 1211-1217.
21. Jacobson KA, Gao ZG (2006). Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5: 247-264. (Pubitemid 43336037)
22. 2 receptors in rat brain. J Pharmacol Exp Ther 251: 888-893.
23. 2A adenosine receptor. Biochim Biophys Acta 1808: 1350-1357.
24. 2A agonists and antagonists. J Med Chem 46: 4847-4859.
25. 2A receptor structures reveal common features of GPCR activation. Nature 474: 521-525.
26. 2Areceptor agonists for the treatment of chronic obstructive pulmonary disease. Bioorg Med Chem Lett 18: 1284-1287.
27. 2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data. Bioorg Med Chem Lett 19: 4471-4475.
28. McGuinness R (2007). Impedance-based cellular assay technologies: recent advances, future promise. Curr Opin Pharmacol 7: 535-540.
29. Motulsky HJ, Mahan LC (1984). The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25: 1-9. (Pubitemid 14223246)
30. 2A adenosine receptors. Eur J Pharm Sci 10: 259-265.
31. 2 receptor antagonist, to rat brain membranes. Mol Pharmacol 46: 817-822.
32. Peters MF, Scott CW (2009). Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J Biomol Screen 14: 246-255.
33. Scandroglio P, Brusa R, Lozza G, Mancini I, Petro R, Reggiani A et al. (2010). Evaluation of cannabinoid receptor 2 and metabotropic glutamate receptor 1 functional responses using a cell impedance-based technology. J Biomol Screen 15: 1238-1247.
34. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85. (Pubitemid 16258399)
35. Swinney DC (2004). Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 3: 801-808.
36. Sykes DA, Dowling MR, Charlton SJ (2009). Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 76: 543-551.
37. 2A, and A3 receptor. J Med Chem 45: 420-429.
38. van Tilburg EW, Gremmen M, von Frijtag Drabbe Kunzel JK, de Groote M, IJzerman AP (2003). 2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor. Bioorg Med Chem 11: 2183-2192. (Pubitemid 36457845)
39. Tummino PJ, Copeland RA (2008). Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47: 5481-5492. (Pubitemid 351711169)
40. Vauquelin G, Charlton SJ (2010). Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161: 488-508.
41. Vauquelin G, van Liefde I (2006). Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci 27: 356-359.
42. Verzijl D, IJzerman AP (2011). Functional selectivity of adenosine receptor ligands. Purinergic Signal 7: 171-192.
43. Xi B, Yu N, Wang X, Xu X, Abassi YA (2008). The application of cell-based label-free technology in drug discovery. Biotechnol J 3: 484-495. (Pubitemid 351618734)
44. 2A adenosine receptor. Science 332: 322-327.
45. Yu N, Atienza JM, Bernard J, Blanc S, Zhu J, Wang X et al. (2006). Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors. Anal Chem 78: 35-43. (Pubitemid 43050137)
46. Zhang R, Monsma F (2009). The importance of drug-target residence time. Curr Opin Drug Discov Devel 12: 488-496.
47. 2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol 117: 1381-1386.